A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
The US FDA issued alerts recently regarding the recalls of five ocular lubricant products and one generic glaucoma medication. BRS Analytical Services, a contract testing laboratory based in St. Lo...
Ophthalmic diagnostic company Intalight announced May 15 that it had received CE marking for its Dream optical coherence tomography (OCT) platform. Intalight, with offices in San Jose, California, ...
Bausch + Lomb announced May 7 that the LuxLife trifocal intraocular lens (IOL) had received CE marking in Europe. The company said the nondiffractive LuxLife has an uninterrupted, continuous refrac...
Alcon reported May 13 that its Q1-2025 net sales were $2.45 billion, on par with $2.44 billion in Q1-2024 and up 3 percent on a constant currency basis. Surgical net sales totaled $1.33 billion (do...
Lenz Therapeutics announced May 9 a license agreement with Taiwan’s Lotus Pharmaceutical for exclusive rights to market LNZ100 (1.75% aceclidine) for presbyopia in South Korea and certain countries...
Viridian Therapeutics announced May 7 that the US FDA had granted breakthrough therapy status to veligrotug, the company’s anti-insulin-like growth factor-1 receptor (IGF-1R) candidate for thyroid ...
Unity Biotechnology announced May 5 that it would reduce its workforce and seek an established ophthalmic company to continue the development of UBX1325, a Tie2/anti-VEGF bispecific antibody candid...
Carl Zeiss Meditec announced May 7 that Markus Weber, PhD, the company’s president and CEO, will step down of his own accord, effective May 31. Replacing Weber will be Maximilian Foerst, currently ...
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
A Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.